- 全部删除
您的购物车当前为空
CDK9-IN-7 (compound 21e) 是一种高效选择性的,具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干细胞特性。


为众多的药物研发团队赋能,
让新药发现更简单!
CDK9-IN-7 (compound 21e) 是一种高效选择性的,具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干细胞特性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 742 | In stock | |
| 5 mg | ¥ 1,850 | In stock | |
| 10 mg | ¥ 2,710 | In stock | |
| 25 mg | ¥ 4,130 | In stock | |
| 50 mg | ¥ 5,800 | In stock | |
| 100 mg | ¥ 7,630 | In stock | |
| 200 mg | ¥ 10,300 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 2,380 | In stock |
CDK9-IN-7 相关产品
| 产品描述 | CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM). |
| 靶点活性 | CDK4-CyclinD:148 nM, CDK6-CyclinD:145 nM, CDK9-CyclinT1:11 nM |
| 体外活性 | CDK9-IN-7对包括A549和H1299在内的NSCLC细胞系,表现出极高的抑制效力,其IC50值均低于0.5 µM。即便在耐药的NSCLC细胞系H1975中,CDK9-IN-7仍展现出良好的抑制活性(IC50:0.837 µM)[1]。 |
| 分子量 | 547.71 |
| 分子式 | C29H37N7O2S |
| CAS No. | 2369981-71-3 |
| Smiles | C(N(C)C)(=O)C=1N(C=2C(C1)=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N2)C4CCCC4 |
| 密度 | 1.26 g/cm3 (Predicted) |
| 颜色 | Yellow |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| 溶解度信息 | DMSO: 10 mg/mL (18.26 mM), Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
评论内容